Please login to the form below
Healthcare terms - O
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - O
- Objectives
- Off-label use
- Offensive marketing
- Oligopsony
- Omnibus survey
- One to one marketing (1:1 marketing)
- One-on-one interview
- Online learning
- Open ended question
- Open observation
- Open-label trial
- Opinion leader
- Opportunities to hear (OTH)
- Opportunities to see (OTS)
- Opportunity cost
- Optimising
- Order bias
- Organic growth/development
- Orphan drugs
- Outlier
- Output evaluation
- Outsourcing
- Over the counter (OTC)
COVID-19 Updates and Daily News
Featured jobs
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- Galapagos mid-stage trial failure raises concerns for Gilead deal
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Novartis’ MS therapy Mayzent approved by NICE
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Quick links
Infographics
